- Home
- IDN vs ONCY Comparison
IDN vs ONCY Comparison
Compare IDN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- ONCY
- Stock Information
- Founded
- IDN 1994
- ONCY 1998
- Country
- IDN United States
- ONCY Canada
- Employees
- IDN N/A
- ONCY N/A
- Industry
- IDN Computer Software: Prepackaged Software
- ONCY Pharmaceuticals and Biotechnology
- Sector
- IDN Technology
- ONCY Health Care
- Exchange
- IDN Nasdaq
- ONCY Nasdaq
- Market Cap
- IDN 46.8M
- ONCY 49.1M
- IPO Year
- IDN 1999
- ONCY 1999
- Fundamental
- Price
- IDN $2.83
- ONCY $0.52
- Analyst Decision
- IDN Buy
- ONCY Strong Buy
- Analyst Count
- IDN 2
- ONCY 3
- Target Price
- IDN $3.00
- ONCY $4.33
- AVG Volume (30 Days)
- IDN 47.0K
- ONCY 333.0K
- Earning Date
- IDN 05-13-2025
- ONCY 05-14-2025
- Dividend Yield
- IDN N/A
- ONCY N/A
- EPS Growth
- IDN N/A
- ONCY N/A
- EPS
- IDN N/A
- ONCY N/A
- Revenue
- IDN $19,997,000.00
- ONCY N/A
- Revenue This Year
- IDN $7.60
- ONCY N/A
- Revenue Next Year
- IDN $10.02
- ONCY N/A
- P/E Ratio
- IDN N/A
- ONCY N/A
- Revenue Growth
- IDN 5.77
- ONCY N/A
- 52 Week Low
- IDN $1.92
- ONCY $0.47
- 52 Week High
- IDN $4.46
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- IDN 61.62
- ONCY 41.53
- Support Level
- IDN $2.47
- ONCY $0.54
- Resistance Level
- IDN $2.87
- ONCY $0.65
- Average True Range (ATR)
- IDN 0.17
- ONCY 0.04
- MACD
- IDN 0.03
- ONCY -0.00
- Stochastic Oscillator
- IDN 92.86
- ONCY 13.36
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.